Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Rozanolixizumab in adults with persistent or chronic primary immune thrombocytopenia was terminated, with results posted in August 2023…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rozanolixizumab

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: TERMINATED | Results posted: 2023-08-08